This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Response Genetics, Inc. Reports Second Quarter Financial Results And Operational Update

Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2011.

“With revenue in all of our sales channels increasing and net loss decreasing, Response Genetics continues to trend toward profitability,” said Denise McNairn, Interim CEO of Response Genetics. “And through innovation, both scientific and technical, we remain on track to meet our business objectives as we bring value to our shareholders.”

Second Quarter 2011 Financial Results

Total revenue increased by 18.8 percent to $6.7 million for the second quarter ended June 30, 2011, compared to $5.6 million for the same period last year. The increase was primarily due to increases in pharmaceutical service revenues of $1.6 million. Revenue from ResponseDX™ genetic tests decreased by 15 percent to $3.0 million for the second quarter, compared to $3.5 million for the same period in 2010. The decrease in ResponseDX™ revenue was artificially caused by the one-time revenue adjustment of $1.5 million recorded in the second quarter of 2010 for the adoption of the accrual basis of accounting. Pharmaceutical client revenue increased 74.4 percent to $3.7 million, compared to $2.1 million in the second quarter of 2010.

Cost of revenue was $2.8 million for the second quarter ended June 30, 2011, compared with $2.5 million for the same period in 2010. Research and development expenses were $0.2 million for the second quarter of 2011, compared with $0.4 million for the same period in 2010. General and administrative expenses were $2.3 million for the second quarter, compared with $1.7 million for the same period in 2010. Selling and marketing expenses were $1.4 million for the second quarter of 2011, compared with $1.4 million for the same period in 2010. Total operating expenses for the second quarter were $6.8 million, compared with $6.1 million for the same period last year. The primary reasons for the increase in total operating expenses are costs related to an increase in personnel, consulting, bad debt, and billing service expenses. Stock compensation expense was $0.3 million for the second quarter of 2011, compared to $0.1 million for the same period in 2010.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs